c-MET (K1244R)
Sign in to save this workspaceMET · Variant type: point · HGVS: p.K1244R
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Crizotinib | 98.9% | 1.1% | 91.39 |
| 2 | Cabozantinib | 93.4% | 6.6% | 92.73 |
| 3 | Capmatinib | 90.1% | 9.9% | 99.75 |
| 4 | Tepotinib | 83.4% | 16.6% | 99.75 |
| 5 | Gilteritinib | 83.1% | 16.9% | 88.97 |
| 6 | Deucravacitinib | 72.8% | 27.2% | 98.99 |
| 7 | Pacritinib | 72.5% | 27.5% | 88.64 |
| 8 | Tivozanib | 62.1% | 37.9% | 92.42 |
| 9 | Defactinib | 60.0% | 40.0% | 92.68 |
| 10 | Afatinib | 57.2% | 42.8% | 98.50 |
| 11 | Lenvatinib | 46.3% | 53.7% | 97.74 |
| 12 | Repotrectinib | 44.6% | 55.4% | 84.21 |
| 13 | Neratinib | 41.6% | 58.4% | 93.18 |
| 14 | Canertinib | 38.1% | 61.9% | 96.49 |
| 15 | Erdafitinib | 35.9% | 64.1% | 95.71 |
| 16 | Dacomitinib | 34.9% | 65.1% | 97.99 |
| 17 | Vemurafenib | 32.6% | 67.4% | 96.49 |
| 18 | Pazopanib | 32.1% | 67.9% | 97.49 |
| 19 | Axitinib | 30.0% | 70.0% | 93.23 |
| 20 | Fostamatinib | 28.2% | 71.8% | 96.74 |
| 21 | Selpercatinib | 26.5% | 73.5% | 96.72 |
| 22 | Dabrafenib | 23.0% | 77.0% | 94.74 |
| 23 | Abemaciclib | 21.9% | 78.1% | 91.48 |
| 24 | Brigatinib | 20.3% | 79.7% | 82.96 |
| 25 | Fedratinib | 20.0% | 80.0% | 96.21 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Crizotinib | 98.9% | — | — |
| Cabozantinib | 93.4% | — | — |
| Capmatinib | 90.1% | — | — |
| Tepotinib | 83.4% | — | — |
| Gilteritinib | 83.1% | — | — |
| Deucravacitinib | 72.8% | — | — |
| Pacritinib | 72.5% | — | — |
| Tivozanib | 62.1% | — | — |
| Defactinib | 60.0% | — | — |
| Afatinib | 57.2% | — | — |
| Lenvatinib | 46.3% | — | — |
| Repotrectinib | 44.6% | — | — |
| Neratinib | 41.6% | — | — |
| Canertinib | 38.1% | — | — |
| Erdafitinib | 35.9% | — | — |
| Dacomitinib | 34.9% | — | — |
| Vemurafenib | 32.6% | — | — |
| Pazopanib | 32.1% | — | — |
| Axitinib | 30.0% | — | — |
| Fostamatinib | 28.2% | — | — |
| Selpercatinib | 26.5% | — | — |
| Dabrafenib | 23.0% | — | — |
| Abemaciclib | 21.9% | — | — |
| Brigatinib | 20.3% | — | — |
| Fedratinib | 20.0% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.2ms